We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Guangdong Fapon Biotech Co., Ltd.

Download Mobile App




Protein Biomarker Blood Test Accurately Detects Alzheimer’s Disease

By LabMedica International staff writers
Posted on 07 Jul 2021
A 19-protein biomarker panel distinguished Alzheimer’s disease (AD) patients from healthy individuals with greater than 96% accuracy and differentiated among the early, intermediate, and late stages of AD while monitoring the progression of the disease.

To capitalize on results obtained by studies showing the potential of blood proteins as candidate biomarkers for AD, investigators at Hong Kong University of Science and Technology (China) and their colleagues at University College London (United Kingdom) systematically profiled the plasma proteome to identify novel AD blood biomarkers and develop a high-performance, blood-based test for AD.

To do this, they used a proximity extension assay technique to quantify 1160 plasma proteins in samples obtained from a Hong Kong Chinese cohort. More...
Proximity extension assay (PEA) is a direct one-step protein quantification method using a pair of DNA oligonucleotides linked to antibodies against the target molecule. It requires polyclonal or two monoclonal antibodies that bind to target epitopes close enough to form a DNA duplex which is quantified by real-time PCR.

The results of the PEA analysis identified 429 proteins that were dysregulated in the plasma of AD patients. The investigators selected 19 "hub proteins" representative of the AD plasma protein profile, which were used to form the basis of a scoring system that accurately classified clinical AD (as characterized by the presence of amyloid, tau, phosphorylated tau, and neurodegeneration).

In addition to distinguishing AD patients from healthy individuals with more than 96% accuracy, the system could also differentiate among the early, intermediate, and late stages of AD and be used to monitor the progression of the disease over time.

"With the advancement of ultrasensitive blood-based protein detection technology, we have developed a simple, noninvasive, and accurate diagnostic solution for AD, which will greatly facilitate population-scale screening and staging of the disease," said senior author Dr. Nancy Ip, professor of life science at Hong Kong University of Science and Technology.

The plasma protein screening method for detection of Alzheimer’s disease was described in the May 25, 2021, online edition of Alzheimer's & Dementia: The Journal of the Alzheimer's Association.

Related Links:
Hong Kong University of Science and Technology
University College London




Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
HPV Test
Allplex HPV28 Detection
Gold Member
Automatic Hematology Analyzer
CF9600
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The panel expands Cepheid’s respiratory testing portfolio on the GeneXpert platform, offering laboratories greater flexibility in selecting tests based on clinical needs. (Photo courtesy of Cepheid)

Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis

Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more

Microbiology

view channel
Image: Graphical Abstract (Matthew A Butzler, Jennifer L Reed, Alaina M Olson, et al. Development of a Rapid Automated Point-of-Care Test for Mycobacterium tuberculosis Detection from Tongue Swabs and Sputum Specimens on the DASH® Rapid PCR System, Open Forum Infectious Diseases, 2026; https://doi.org/10.1093/ofid/ofag706)

Point-of-Care Test Detects Tuberculosis from Tongue Swab and Sputum

Tuberculosis remains a major infectious disease challenge, particularly in regions with limited access to diagnostic testing and treatment. Diagnosis can be time-consuming, and collecting sputum samples... Read more

Pathology

view channel
Image Credit: Adobe Stock

New Training Approach Helps AI Distinguish Neighboring Cells in Tissue

Artificial intelligence (AI) can assist with identifying cells in digital pathology images, but densely packed tissue remains difficult to analyze. Neighboring cells may be merged, counted twice, or missed,... Read more

Industry

view channel
Image: The TOMR trial uses Signatera-guided MRD testing to identify high-risk patients for curative-intent treatment.

Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study

Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.